We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rockeby Secures License for Pre-eclampsia Diagnostic Test

By Labmedica staff writers
Posted on 02 Feb 2007
Print article
Rockeby Biomed Ltd (Orchard Rd., Singapore) has entered into a world-wide licensing agreement to license a blood test to diagnose pre-eclampsia. This is a common medical disorder of pregnancy, also called pregnancy-induced hypertension. This is subsequent to the test achieving critical milestones in the first phase of its development.

Rockeby, which has been funding the development of the pre-eclampsia test since August 2005, has secured the licensing agreement with the Queensland-based developer of the test Dr. Victor Voroteliak and his company Diagnoz Pty. Ltd.

Rockeby chief executive Dr. Sze Wee Tan said the company would now fund the second round of the development of the test under a new licensing agreement. This test would also add to the Intellectual Property library that the company is acquiring as it develops diagnostic tests for female healthcare needs.

We have entered into a licensing agreement with Dr. Voroteliak to license the pre-eclampsia test in return for a new round of funding up to July 2007, Dr. Tan said. Once we have completed the last development milestone, we can continue to explore external funding for this project, as we have already licensed the rights to the intellectual property from Dr. Voroteliak with this licensing agreement.

Pre-eclampsia is the most common medical disorder of pregnancy with a reported incidence in the obstetric literature, affecting at least 5-8% of all pregnancies. It is a rapidly progressive condition characterized by high blood pressure and the presence of protein in the urine. Swelling, sudden weight gain, headaches, and changes in vision are important symptoms; however, some women with rapidly advancing disease report few symptoms. Diagnosis is currently symptomatic on the basis of sustained blood pressure > 140/90 mmHg in conjunction with proteinuria (American College of Obstetricians and Gynecologists guidelines). Pre-eclampsia, without intervention, progresses to eclampsia, which is characterized by malignant hypertension and epileptiform convulsions requiring emergency Caesarian sections.



Related Links:
Rockeby Biomed
Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Tabletop Centrifuge
Mikro 185
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.